Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Helius Medical Technologies Inc Class A (HSDT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/16/2025: HSDT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.8% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.67M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.13 | 52 Weeks Range 0.17 - 18.13 | Updated Date 06/30/2025 |
52 Weeks Range 0.17 - 18.13 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -26.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8185.71% |
Management Effectiveness
Return on Assets (TTM) -195.57% | Return on Equity (TTM) -800% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -410272 | Price to Sales(TTM) 1.53 |
Enterprise Value -410272 | Price to Sales(TTM) 1.53 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA -0.01 | Shares Outstanding 3155110 | Shares Floating 467213 |
Shares Outstanding 3155110 | Shares Floating 467213 | ||
Percent Insiders 17.7 | Percent Institutions 6.31 |
Analyst Ratings
Rating 1 | Target Price 4 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Helius Medical Technologies Inc Class A
Company Overview
History and Background
Helius Medical Technologies, Inc. (HSDT) was founded to develop and commercialize the Portable Neuromodulation Stimulator (PoNSu2122) device, a non-invasive medical device designed to stimulate neural pathways to improve neurological function. The company has focused on clinical trials, regulatory approvals, and market access for its technology.
Core Business Areas
- Neuromodulation: Focuses on the development, manufacturing, and commercialization of the PoNS device.
Leadership and Structure
Helius Medical Technologies has a management team led by Dane C. Miller, Ph.D., Interim Chief Executive Officer, as of November 2023. The organizational structure consists of various departments including research and development, clinical operations, regulatory affairs, sales, and marketing.
Top Products and Market Share
Key Offerings
- PoNS Device: The Portable Neuromodulation Stimulator (PoNS) is Helius Medical's primary product. It delivers mild electrical stimulation to the tongue to enhance neuroplasticity and improve balance and gait in patients with neurological conditions. Competitors include companies offering other neuromodulation therapies and rehabilitation services. Market share data is not widely available. Number of users is currently limited due to the phased market rollout.
Market Dynamics
Industry Overview
The neuromodulation industry is growing, driven by increasing prevalence of neurological disorders, technological advancements, and rising demand for non-invasive therapies. It is highly regulated and competitive.
Positioning
Helius Medical Technologies is positioned as an innovator in non-invasive neuromodulation using the PoNS device. Competitive advantages include the novelty of its tongue stimulation approach, and clinical studies.
Total Addressable Market (TAM)
The TAM for neuromodulation in neurological disorders, specifically related to balance and gait issues in multiple sclerosis patients and traumatic brain injuries is large. Helius' positioning depends on its ability to secure regulatory approvals, market adoption, and demonstrate clinical effectiveness and safety.
Upturn SWOT Analysis
Strengths
- Novel PoNS technology
- Non-invasive approach
- Potential for improved patient outcomes
- Addressable Market
Weaknesses
- Limited commercialization history
- Dependence on single product (PoNS)
- Requires extensive funding for R&D and marketing
- Regulatory risk and market access challenges
- High costs
Opportunities
- Expansion into new indications (e.g., other neurological disorders)
- Strategic partnerships
- International market expansion
- Further clinical trial data to support efficacy
Threats
- Competition from established neuromodulation companies
- Adverse regulatory decisions
- Lack of insurance coverage
- Slow adoption by clinicians and patients
- Negative or inconclusive Clinical Trials
Competitors and Market Share
Key Competitors
- BMRA
- INZY
- EVGN
Competitive Landscape
Helius Medical Technologies competes with established neuromodulation companies and rehabilitation services. Its advantage lies in the novel PoNS technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the early stage of commercialization.
Future Projections: Future growth depends on successful commercialization of the PoNS device, regulatory approvals in new markets, and ability to raise money.
Recent Initiatives: Recent initiatives include efforts to secure regulatory approvals, build partnerships, and conduct clinical trials.
Summary
Helius Medical Technologies is a high-risk, high-reward company focused on neuromodulation with the PoNS device. The company's prospects depend on successfully demonstrating clinical efficacy, securing regulatory approvals, and achieving broader market adoption. Cash flow is weak and the company will need to continue to raise capital. They will need to demonstrate a higher success rate in getting their product to market. They are an innovative company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Helius Medical Technologies' Investor Relations website
- SEC filings (10-K, 10-Q)
- Company press releases
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Helius Medical Technologies Inc Class A
Exchange NASDAQ | Headquaters Newtown, PA, United States | ||
IPO Launch date 2014-06-27 | President, CEO & Director Mr. Dane Carl Andreeff | ||
Sector Healthcare | Industry Medical Devices | Full time employees 21 | Website https://heliusmedical.com |
Full time employees 21 | Website https://heliusmedical.com | ||
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non- implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.